Mario R. Ehlers

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers et al. · Diabetes · 2013 · 405 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

S. Alice Long, Mary Rieck, Srinath Sanda et al. · Diabetes · 2012 · 310 citations · Full text

Life Sciences, Endocrinology, Immunology +17

Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme.

Mario R. Ehlers, Edward A. Fox, Daniël J. Strydom et al. · Proceedings of the National Academy of Sciences · 1989 · 297 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +9

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

Mark Rigby, Kristina M. Harris, Ashley Pinckney et al. · Journal of Clinical Investigation · 2015 · 292 citations · Full text

Medicine, Endocrinology, Immunology +17

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

S. Alice Long, Jerill Thorpe, Hannah A. DeBerg et al. · Science Immunology · 2016 · 249 citations

Life Sciences, Endocrinology, Immunology +17